Skip to main content
Erschienen in: Journal of Hematology & Oncology 1/2018

Open Access 01.12.2018 | Correction

Correction to: PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse

verfasst von: Bingxin Zheng, Tingting Ren, Yi Huang, Kunkun Sun, Shidong Wang, Xing Bao, Kuisheng Liu, Wei Guo

Erschienen in: Journal of Hematology & Oncology | Ausgabe 1/2018

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN
Hinweise
The original article can be found online at https://​doi.​org/​10.​1186/​s13045-018-0560-1.

Erratum

The original article [1] contained an error in Table 1 whereby the ‘Positive’ column in the ‘PD-L1’ Tumor type group of columns was mistakenly included at the beginning of the ‘PD-L2’ Tumor type group of columns.
This error has now been corrected. Furthermore, this error was not the fault of the authors, and was instead mistakenly carried forward by the production team that handled this article.
Table 1
Expression of PD-L1, PD-L2, and PD-1 in musculoskeletal tumors
Tumor
N
PD-L1
N (%)
PD-L2
N (%)
PD-1
N (%)
0
1+
2+
3+
Positive
0
1+
2+
3+
Positive
0
1+
2+
3+
Positive
Musculoskeletal tumor
234
179
35
10
10
55 (23.5%)
168
49
8
9
66 (28.2%)
185
37
5
7
49 (20.9%)
Giant cell tumor
14
4
1
2
7
10 (71.4%)
7
1
1
5
7 (50.0%)
6
1
2
5
8 (57.1%)
Osteosarcoma
62
40
17
3
2
22 (35.5%)
36
21
3
2
26 (41.9%)
45
15
1
1
17 (27.4%)
Synovial sarcoma
127
107
16
3
1
20 (15.7%)
101
22
2
2
26 (20.5%)
103
21
2
1
24 (18.9%)
Chondrosarcoma
31
28
1
2
0
3 (9.7%)
24
5
2
0
7 (22.6%)
31
0
0
0
0
Conventional chondrosarcoma
27
27
0
0
0
0
21
4
2
0
6 (22.2%)
27
0
0
0
0
Dedifferentiated chondrosarcoma
4
1
1
2
0
3 (75.0%)
3
1
0
0
1 (25.0%)
4
0
0
0
0
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
download
DOWNLOAD
print
DRUCKEN

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

e.Med Innere Medizin

Kombi-Abonnement

Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.

Literatur
1.
Zurück zum Zitat Zheng B. PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse. J Hematol Oncol. 2018;11:16.CrossRefPubMedPubMedCentral Zheng B. PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse. J Hematol Oncol. 2018;11:16.CrossRefPubMedPubMedCentral
Metadaten
Titel
Correction to: PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse
verfasst von
Bingxin Zheng
Tingting Ren
Yi Huang
Kunkun Sun
Shidong Wang
Xing Bao
Kuisheng Liu
Wei Guo
Publikationsdatum
01.12.2018
Verlag
BioMed Central
Erschienen in
Journal of Hematology & Oncology / Ausgabe 1/2018
Elektronische ISSN: 1756-8722
DOI
https://doi.org/10.1186/s13045-018-0580-x

Weitere Artikel der Ausgabe 1/2018

Journal of Hematology & Oncology 1/2018 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.